Havemeyer Place LP Purchases Shares of 7,688 Gilead Sciences, Inc. $GILD

Havemeyer Place LP purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 7,688 shares of the biopharmaceutical company’s stock, valued at approximately $944,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank bought a new stake in shares of Gilead Sciences during the fourth quarter worth about $2,617,152,000. Massachusetts Financial Services Co. MA increased its position in shares of Gilead Sciences by 3,763.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after acquiring an additional 4,113,999 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after acquiring an additional 2,113,692 shares in the last quarter. First Trust Advisors LP increased its position in shares of Gilead Sciences by 154.3% during the third quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock worth $342,910,000 after acquiring an additional 1,874,508 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of Gilead Sciences by 12.0% during the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after acquiring an additional 1,618,453 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

GILD has been the subject of several recent research reports. Royal Bank Of Canada reissued an “overweight” rating and set a $122.00 target price on shares of Gilead Sciences in a research report on Monday, June 1st. Morgan Stanley decreased their target price on shares of Gilead Sciences from $175.00 to $168.00 in a research report on Friday, May 8th. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Rothschild & Co Redburn decreased their target price on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Finally, The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research report on Friday, April 17th. Twenty-six investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $156.93.

Gilead Sciences Price Performance

GILD opened at $129.16 on Monday. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The stock has a market cap of $160.36 billion, a price-to-earnings ratio of 17.60 and a beta of 0.31. Gilead Sciences, Inc. has a twelve month low of $104.46 and a twelve month high of $157.29. The company’s 50-day moving average price is $134.38 and its two-hundred day moving average price is $134.38.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s payout ratio is presently 44.69%.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Citi and Scotiabank both reiterated bullish views on Gilead, with each firm maintaining a Buy rating, which can support investor confidence in the stock. Gilead Sciences (GILD) Receives a Buy from Citi
• Positive Sentiment: Gilead highlighted progress on lenacapavir in South Africa, where the government and Global Fund are accelerating access to the HIV prevention drug, reinforcing the company’s growth story in HIV. Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
• Positive Sentiment: Gilead and Lakefront completed the acquisition of Ouro Medicines, expanding the inflammation/autoimmune pipeline around gamgertamig, a potential first-in-class T cell engager. Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
• Positive Sentiment: Gilead’s inclusion in a list of “best quality growth stocks” may add to the market’s view that the company remains a high-quality large-cap healthcare name. 5 Best Quality Growth Stocks to Buy
• Neutral Sentiment: Industry-wide biopharma M&A remains active, and Gilead was mentioned among the sector’s deal-making leaders, which keeps takeover speculation and pipeline deal optionality in focus. Gilead, Merck, Eli Lilly Lead $106 Billion Biopharma Takeover Wave In 2026
• Neutral Sentiment: Gilead also reported a clinical milestone in its IDEAL PBC trial, which could become a future catalyst if the study continues to progress positively. Gilead’s IDEAL PBC Trial Reaches Key Milestone, Setting Up a New Liver Disease Catalyst

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the sale, the insider directly owned 125,779 shares in the company, valued at approximately $16,513,524.91. This represents a 18.21% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the sale, the chief executive officer owned 617,567 shares in the company, valued at $81,185,357.82. The trade was a 2.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 68,000 shares of company stock worth $9,047,570 over the last three months. 0.30% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.